

SEQUENCE LISTING

5 <110> Nycomed Imaging AS

 <120> Improvements in or relating to diagnostic/therapeutic
 agents

10 <130> REF/Klaveness/993

 <140> US 08/958,993

 <141> 1997-10-28

15 <160> 25

 <170> PatentIn Ver. 2.1

 <210> 1

20 <211> 4

 <212> PRT

 <213> Artificial Sequence

 <220>

25 <223> Description of Artificial
 Sequence:RGDC-Mal-PEG3400-DSPE

 <400> 1

 Arg Gly Asp Cys

30 1

 <210> 2

 <211> 25

35 <212> PRT

 <213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Peptide
comprising phosphatidylserine-binding and
heparin-binding sections

5

<400> 2

Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Ala Ala
1 5 10 15

10 Ala Trp Glu Pro Pro Arg Ala Arg Ile
20 25

<210> 3

15 <211> 8

<212> PRT

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence:Heparin-binding
peptide

<400> 3

Trp Glu Pro Pro Arg Ala Arg Ile

25 1 5

<210> 4

<211> 6

30 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Linker sequence

35

<220>

<221> MOD_RES

007664-033260
TOGETHER

<222> (1)

<223> MTX-phenylalanine

<400> 4

5 Phe Lys Leu Arg Leu Cys
1 5

<210> 5

10 <211> 4

<212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:Heparin
sulphate binding peptide

<400> 5

20 Lys Arg Lys Arg
1

<210> 6

<211> 8

25 <212> PRT

<213> Artificial Sequence

<220>

30 <223> Description of Artificial Sequence:Fibronectin
peptide

<400> 6

35 Trp Gln Pro Pro Arg Ala Arg Ile
1 5

<210> 7

007654-012204
T02210-455260

<211> 13
<212> PRT
<213> Artificial Sequence

5 <220>
<223> Description of Artificial Sequence:Lipopeptide
consisting of a heparin sulphate binding peptide
and a fibronectin peptide

10 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-lysine

15 <400> 7
Lys Lys Arg Lys Arg Trp Gln Pro Pro Arg Ala Arg Ile
1 5 10

20 <210> 8
<211> 24
<212> PRT
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:Fibronectin
peptide sequence

<400> 8
30 Phe Asn Phe Arg Leu Lys Ala Gly Gln Lys Ile Arg Phe Gly Gly Gly
1 5 10 15

Gly Trp Gln Pro Pro Arg Ala Ile
20

35

<210> 9

<212> PRT

5 <220>

<220>

<222> (1)

<400> 9

<210> 10

20 <211> 10

<212> PRT

<220>

<220>

<221> MOD_RES

30 $\langle 222 \rangle$ (1)

<220>

<221> MOD_RES

35 $\langle 222 \rangle$ (10)

<223> AMIDATION

<400> 10

Gly Pro Arg Pro Pro Glu Arg His Gln Ser

1

5

10

5

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:Lipopeptide
containing RGD sequence and fluorescein reporter
group

15

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

20

<220>

<221> MOD_RES

<222> (4)

<223> Acetyl-RGD-K-fluorescein side chain

25

<400> 11

Lys Lys Lys Lys Gly

1

5

30

<210> 12

<211> 18

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence:Endothelial

<220>
 <221> MOD_RES
 5 <222> (1)
 <223> 2-n-hexadecylstearyl-Lys

 <220>
 <221> MOD_RES
 10 <222> (18)
 <223> AMIDATION

 <400> 12
 Lys Leu Ala Leu Lys Leu Ala Leu Lys Ala Leu Lys Ala Ala Leu Lys
 15 1 5 10 15

 Leu Ala

 20
 <210> 13
 <211> 4
 <212> PRT
 <213> Artificial Sequence
 25
 <220>
 <223> Description of Artificial Sequence:Lipopeptide
 functionalised with captopril

 30 <220>
 <221> MOD_RES
 <222> (1)
 <223> Dipalmitoyl-Lys

 35 <220>
 <221> MOD_RES
 <222> (4)

<223> Amide linked via side chain to captopril

<220>

<221> MOD_RES

5 <222> (4)

<223> AMIDATION

<400> 13

Lys Lys Lys Lys

10 1

<210> 14

<211> 13

15 <212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:Lipopeptide
with an affinity for endothelial cells

20

<220>

<221> MOD_RES

<222> (1)

25 <223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

<222> (4)

30 <223> Acp

<220>

<221> MOD_RES

<222> (13)

35 <223> AMIDATION

<400> 14

092664-04004
T02270-7939250

Lys Lys Lys Xaa Ile Arg Arg Val Ala Arg Pro Pro Leu
1 5 10

5 <210> 15
<211> 14
<212> PRT
<213> Artificial Sequence

10 <220>
<223> Description of Artificial Sequence:Lipopeptide
comprising an interleukin-1 receptor binding
peptide

15 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

20 <400> 15-
Lys Gly Asp Trp Asp Gln Phe Gly Leu Trp Arg Gly Ala Ala
1 5 10

25 <210> 16
<211> 12
<212> PRT
<213> Artificial Sequence

30 <220>
<221> MOD_RES
<222> (1)
<223> Dabsyl-Tyr

35 <220>
<221> MOD_RES
<222> (10)

TOGETHER

<223> RGDS chain linked via NH2 group of lysine

<220>

5 <223> Description of Artificial Sequence: Branched core
peptide comprising a dabsylated atherosclerotic
plaque-binding sequence and RGDS

<400> 16

10 Tyr Arg Ala Leu Val Asp Thr Leu Lys Lys Gly Cys
1 5 10

<210> 17

15 <211> 25

<212> DNA

<213> Artificial Sequence

<220>

20 <223> Description of Artificial Sequence: Synthetic
oligonucleotide

<220>

<221> misc_feature

<222> (1)

25 <223> Biotinylated

<400> 17

gaaaggtagt ggggtcgtgt gccgg

25

30

<210> 18

<211> 15

<212> PRT

<213> Artificial Sequence

35

<220>

<223> Description of Artificial Sequence: Lipopeptide

with affinity for thrombi

5 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

10 <220>
<221> MOD_RES
<222> (15)
<223> AMIDATION

15 <400> 18
Lys Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
1 5 10 15

20 <210> 19
<211> 6
<212> PRT
<213> Artificial Sequence

25 <220>
<223> Description of Artificial Sequence:Lipopeptide

30 <220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

35 <220>
<221> MOD_RES
<222> (5)
<223> Biotinylated-Lys

<400> 19
Lys Trp Lys Lys Lys Gly

	1	5	
			<210> 20
5			<211> 5
			<212> PRT
			<213> Artificial Sequence
			<220>
10			<223> Description of Artificial
			Sequence:Thiol-functionalised lipid molecule
			<220>
			<221> MOD_RES
15			<222> (1)
			<223> Dipalmitoyl-Lys
			<220>
			<221> MOD_RES
20			<222> (4)
			<223> Acp
			<400> 20
			Lys Lys Lys Xaa Cys
25	1	5	
			<210> 21
30			<211> 4
			<212> PRT
			<213> Artificial Sequence
			<220>
35			<223> Description of Artificial Sequence:Lipopeptide
			functionalised with atenolol

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

5

<220>

<221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to
atenolol

10

<220>

<221> MOD_RES

<222> (4)

<223> AMIDATION

15

<400> 21

Lys Lys Lys Lys

1

20

<210> 22

<211> 4

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Lipopeptide
containing folic acid

30

<220>

<221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

35

<220>

<221> MOD_RES

<222> (4)
<223> AMIDATION

<220>

5 <221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to
folic acid

10 <400> 22

Lys Lys Lys Lys

1

15 <210> 23

<211> 4

<212> PRT

<213> Artificial Sequence

20 <220>

<223> Description of Artificial Sequence:Lipopeptide
containing a derivative of bestatin

<220>

25 <221> MOD_RES

<222> (1)

<223> Dipalmitoyl-Lys

<220>

30 <221> MOD_RES

<222> (4)

<223> AMIDATION

<220>

35 <221> MOD_RES

<222> (4)

<223> Lysine with side chain linked via amide bond to

derivative of bestatin

<400> 23

Lys Lys Lys Lys

5 1

<210> 24

<211> 4

10 <212> PRT

<213> Artificial Sequence

<220>

15 <223> Description of Artificial Sequence:Lipopeptide
containing chlorambucil

<220>

<221> MOD_RES

<222> (1)

20 <223> Dipalmitoyl-Lys

<220>

<221> MOD_RES

<222> (4)

25 <223> AMIDATION

<220>

<221> MOD_RES

<222> (4)

30 <223> Lysine with side chain linked via amide bond to
chlorambucil

<400> 24

Lys Lys Lys Lys

35 1

20250404 14:29:20

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

5

<220>
<223> Description of Artificial Sequence:Lipopeptide
functionalised with sulfoxazole

10

<220>
<221> MOD_RES
<222> (1)
<223> Dipalmitoyl-Lys

15

<220>
<221> MOD_RES
<222> (4)
<223> AMIDATION

20

<220>
<221> MOD_RES
<222> (4)
<223> Lysine with side chain linked via amide bond to
sulfoxazole

25

<400> 25
Lys Lys Lys Lys
1

30

<210> 26
<211> 9
<212> PRT
<213> Artificial Sequence

35

<220>
<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

<400> 26

Tyr Arg Ala Leu Val Asp Thr Leu Lys

1

5

5

<210> 27

<211> 16

<212> PRT

<213> Artificial Sequence

10

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

15

<400> 27

Tyr Ala Lys Phe Arg Glu Thr Leu Glu Asp Thr Arg Asp Arg Met Tyr

1

5

10

15

20

<210> 28

<211> 17

<212> PRT

<213> Artificial Sequence

25

<220>

<223> Description of Artificial Sequence:Atherosclerotic
plaque-binding peptide

<400> 28

30

Arg Ala Leu Val Asp Thr Glu Phe Lys Val Lys Gln Glu Ala Gly Ala

1

5

10

15

Lys

35

<210> 29

007654-0134
TOP SECRET

<213> Artificial Sequence

<223> Description of Artificial Sequence:Thrombus
binding peptide

10 Asn Asp Gly Asp Phe Glu Glu Ile Pro Glu Glu Tyr Leu Gln
 1 5 10

<213> Artificial Sequence

20 <223> Description of Artificial Sequence:Thrombus
binding peptide

Gly Pro Arg Gly
25 1

<213> Artificial Sequence

35 <223> Description of Artificial Sequence:Platelet
binding peptide

<400> 31

10

15

[illegible]